Dr RR Baliga's "Got Knowledge Doc" Podkast

The new Lancet Series on ultra-processed foods offers a striking insight: as UPFs rise globally, traditional whole-food diets decline—bringing nutrient imbalance, overeating, toxic exposures, and hyper-palatable formulations that quietly reshape health trajectories. 🍔➡️⚠️   Across more than 100 prospective studies and multiple trials, higher UPF intake consistently links to obesity, type 2 diabet...

Home-delivered DASH-patterned groceries paired with dietitian counseling meaningfully lowered blood pressure and LDL cholesterol among Black adults living in food deserts 🥗📉—as demonstrated in the GoFresh randomized trial (JAMA).   An accompanying editorial highlights why future "food-as-medicine" programs must prioritize underconsumed, health-promoting foods and align with modern evidence favor...

🩺 New insights in hemodialysis care. A major New England Journal of Medicine study reports that daily supplementation with long-chain omega-3 fatty acids (eicosapentaenoic acid and docosahexaenoic acid) led to a 43% reduction in serious cardiovascular events among adults receiving maintenance hemodialysis. 🐟💙   In a population where traditional cardioprotective therapies often fall short, these...

🚀 A milestone moment in lipid therapeutics! The new JAMA trial on the oral PCSK9 inhibitor Enlicitide reports a ~60% reduction in LDL-C , with parallel decreases in ApoB and Lp(a) —all on top of maximally tolerated statin therapy.   For individuals with heterozygous familial hypercholesterolemia (HeFH) —where reaching LDL targets remains a persistent challenge—this represents a major advance. An...

☕ DECAF Trial insight! A new JAMA study shows that daily caffeinated coffee may lower recurrence of atrial fibrillation compared with abstinence. Patients drinking ~1 cup/day had 47% recurrence vs 64% with abstinence (HR 0.61, p=0.01) 📉💓 No major safety concerns—challenging long-held beliefs that coffee is proarrhythmic.   💡Takeaway: For many patients with AF, enjoying their morning brew may b...

🚨 New insights from The Lancet 🚨   A major individual-patient-data meta-analysis (6 RCTs, 8,836 patients) shows that complete revascularisation in acute myocardial infarction significantly reduces cardiovascular death, all-cause mortality, and recurrent MI. 💓📉   Benefits were consistent across age, sex, STEMI/NSTEMI , and lesion characteristics — strengthening the case for a more comprehensive...

🧬 New NEJM data on Olezarsen! In patients with severe hypertriglyceridemia , monthly RNA-targeted therapy delivered major triglyceride reductions (−62% to −72%) and a significant drop in acute pancreatitis risk (rate ratio 0.15).   ✨ Improvements extended to ApoC-III , remnant cholesterol , and non-HDL cholesterol , with consistent benefits across both CORE-TIMI trials.   💡 A promising step for...

📘 New Evidence from NEJM In a large meta-analysis of 17,801 patients with preserved LVEF after MI, beta-blockers did not reduce death, recurrent MI, or heart failure. Event rates were low, and outcomes were similar with or without therapy. 🫀📊   This clarifies practice for a growing post-MI population with LVEF ≥50%—precision matters more than tradition. 🎯   Full study: New England Journal of M...

📢 ADAPT AF-DES Trial — A Safer Path Forward! In patients with atrial fibrillation beyond 1 year after drug-eluting stent implantation, NOAC monotherapy delivered striking benefits over combination therapy. ✅ Lower net adverse clinical events ✅ Marked reduction in major/CRNM bleeding ✅ Similar ischemic protection A beautifully simple strategy with meaningful impact. Published in NEJM (2025) ....

🌊 OCEAN Trial offers fresh insight into antithrombotic therapy after successful AF ablation. In 1284 patients followed for 3 years, event rates were remarkably low 🌟. Rivaroxaban did not show superiority over aspirin for preventing stroke, systemic embolism, or covert embolic events, while bleeding risk was higher with anticoagulation.   🧠 96% had no new infarcts on MRI at follow-up.   Publishe...

🧠 John Locke: Experience • Liberty • Toleration   Born a physician-philosopher, Locke championed empiricism — the idea that knowledge begins with experience, not dogma. His tabula rasa shaped modern psychology, while his Two Treatises of Government defined rights, consent, and freedom that echo through modern democracies.   For clinicians, his legacy reminds us to: 🔹 Trust observation and eviden...

🚀 VESALIUS-CV delivers powerful evidence : in high-risk patients without prior MI or stroke, evolocumab significantly reduced 3-point MACE by 25% and 4-point MACE by 19% , with LDL-C lowered to a median of 45 mg/dL .   💡 These results expand the horizon of prevention, showing that deep LDL reduction is both safe and effective in averting first cardiovascular events.   🫀 Strong science. Clear si...

🫀 Septic Shock, Refined at the Fingertips ⏱️   A powerful new JAMA (2025) trial brings us one step closer to truly personalized resuscitation. The ANDROMEDA-SHOCK-2 study shows that targeting capillary refill time (CRT) — a simple bedside sign — can shorten time on organ support vs usual care, without increasing mortality.   Key insight: Sometimes the most elegant solutions are low-tech, high-tou...

🚨 SOFA-2 arrives — a thoughtful evolution in critical care scoring 🧠🫁🫀   After nearly 30 years, the SOFA score has been modernized using data from >3.3 million ICU patients across 9 countries. The updated SOFA-2 incorporates contemporary respiratory and cardiovascular supports (HFNC, NIPPV, vasopressors, ECMO) and refines thresholds while preserving simplicity and bedside usability.   A meanin...

SOFA-2 is here — a major advance in assessing organ dysfunction in critical illness 🧠🫁❤️   Three decades after the original SOFA score, this updated framework reflects modern ICU practice — integrating contemporary organ support (ventilation, vasopressors, RRT), delirium recognition, and global feasibility across resource settings 🌍📊   Validated in 3.3M+ ICU patients across 9 countries — a rem...

💔 Peripartum Cardiomyopathy: When a Mother's Heart Fights for Two   Peripartum cardiomyopathy is a leading yet often missed cause of maternal morbidity and mortality—striking late in pregnancy or months postpartum. Early suspicion, timely echo, and guideline-directed therapy save lives. 🩺   🧠 Bromocriptine, careful anticoagulation, and multidisciplinary care are reshaping outcomes, but global d...

Rethinking "default lines" in the ICU 🧠🚑   A landmark NEJM trial shows that in patients with shock, deferring arterial catheterization and using automated cuff monitoring was noninferior for 28-day mortality — and reduced catheter-related complications.   A gentle reminder: not every sick patient needs a needle to be well cared for.   Precision isn't only invasive — sometimes it's thoughtful, me...

🌙 Bright Nights, Higher Heart Risk ❤️‍🩹   New findings in JAMA Network Open highlight that greater exposure to artificial light at night is associated with significantly increased risks of coronary artery disease, myocardial infarction, heart failure, atrial fibrillation, and stroke — independent of sleep duration, lifestyle factors, and genetics.   💡 Clinical takeaway: Protecting circadian rhy...

The immune clock starts earlier than we think ⏳🧬   A landmark Nature study shows that immune aging begins quietly in midlife — decades before clinical frailty.   Using >16M single-cell profiles and longitudinal vaccine responses, researchers found: • Stable, early transcriptional drift in naïve & memory T cells • A subtle TH2 shift that may weaken antiviral antibody quality • Reduced IgG class-s...

🫀 TAVR or SAVR? The 7-Year Truth   New 7-year results from the PARTNER-3 trial (NEJM) show that in low-risk patients with severe symptomatic aortic stenosis, TAVR holds pace with surgery — delivering comparable survival, stroke rates, rehospitalization, valve durability, and quality-of-life outcomes.   🔎 Highlights • Composite events: 34.6% (TAVR) vs 37.2% (SAVR) • Mortality: 19.5% vs 16.8% • Va...

🌿 Spinoza: Reason, Nature, Freedom   Today's deck explores Baruch Spinoza — the quietly revolutionary Dutch philosopher who shaped rationalism, modern biblical criticism, and secular democracy.   He saw God = Nature , championed intellectual freedom , and argued that understanding our emotions transforms them — not far from cognitive-behavioral ideas we use in modern medicine.   His reminder feel...

A new era for complex mitral regurgitation. The ENCIRCLE pivotal trial in The Lancet reports that fully percutaneous, transfemoral, transseptal TMVR (SAPIEN M3) achieved durable MR reduction (≈96% ≤1+ at 1 year), low early mortality, and meaningful improvement in symptoms and quality of life for patients unsuitable for surgery or TEER.   A third pathway for mitral disease is emerging—one built on...

🧬 Can we rejuvenate the aging immune system?   A remarkable Nature Biotechnology study shows that a rare population of periostin-positive mesenchymal niche cells can rebuild the adult thymus , recruit new T-cell progenitors, and restore immune responses after injury.   By harnessing CCL19-expressing stromal support, the authors demonstrate a path toward immune renewal in aging, cancer therapy rec...

🩺🎗️ Cardio-Oncology Insight: Not Every Breast Cancer Survivor Needs a Cardiologist   As breast cancer survivorship grows, understanding who truly benefits from long-term cardiac follow-up becomes essential. An important editorial in JAMA Oncology underscores a key principle: risk-stratified care, not reflex surveillance .   👩‍⚕️🔍 Age and traditional cardiovascular risk factors outweigh treatmen...

🧬 Can we rejuvenate the aging immune system? A new Nature Aging trial suggests we might be closer than we thought.   In 50 healthy adults aged 45–70, urolithin A —a mitophagy activator—improved immune fitness over just 28 days: ✅ ↑ naïve CD8⁺ T cells ✅ ↓ exhaustion markers (TOX) ✅ ↑ mitochondrial biogenesis (PGC-1α) ✅ ↑ fatty-acid oxidation capacity ✅ ↑ NK cell and monocyte function ✅ ↑ bac...